Analyzing amino acid-specific KRAS mutations in the three cancer types responsible for most KRAS mutations, the most common KRAS mutation in NSCLC adenocarcinoma subtype is KRASG12C (glycine to cysteine) (33.4%), while the most common KRAS mutation in colon and rectal adenocarcinoma and pancreatic ductal adenocarcinoma is KRASG12D (glycine to aspartate) (32.7, 32.5, and 46.1%, respectively) [39]. This evidence concerns the gene KRAS and cancer.